Counseling
Conditions
Keywords
Opioid Use Disorder, Behavioral Counseling, Peer Recovery Specialist, Buprenorphine
Brief summary
Participants include persons receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center or buprenorphine treatment by telemedicine and Recovery Guide counseling in a church or faith-based community organization. Participants are interviewed at the outset of treatment, after 4 to 6 weeks, and then at 10 to 12 weeks of treatment. The study is an observational study aimed at evaluating the experiences and response to treatment of participants.
Detailed description
Participants include persons receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center or buprenorphine treatment by telemedicine and Recovery Guide counseling in a church or faith-based community organization. Participants are interviewed at the outset of treatment, after 4 to 6 weeks, and then at 10 to 12 weeks of treatment. The study is an observational study aimed at evaluating the experiences and response to treatment of participants. Interviews use a semi-structured format assessing current and past opioid and other substance use, adherence to buprenorphine, and experiences with the counseling and other services provided.
Interventions
BEHAVIORALRecovery Guide Counseling
Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
Sponsors
National Institute on Drug Abuse (NIDA)
Boston University
University of Maryland, College Park
Yale University
Unity Health Care, Inc.
Howard University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Opioid use disorder * Initiating buprenorphine treatment
Exclusion criteria
* Inability to understand the study protocol or assessment questions * Severe medical or psychiatric co-morbidity, including active psychosis, high risk for suicide, or medical contraindications to buprenorphine (e.g., allergy or sensitivity to buprenorphine), * Currently (or in the past 30 days) receiving MAT for OUD.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Retention | 12 weeks | Proportion of participants continuing to receive buprenorphine treatment at 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Medication adherence | 12 weeks | Percent days self-reported medication adherence |
| Treatment satisfaction | 12 weeks | Self-reported satisfaction with treatment |
Other
| Measure | Time frame | Description |
|---|---|---|
| Self-reported opioid and other drug use | 12 weeks | Self-reported drug use |
| Health-related quality of life | 12 weeks | Self-reported health-related quality of life |
Countries
United States
Contacts
Primary ContactRichard Schottenfeld, M.D.
Backup ContactDenise Scott, Ph.D.
Outcome results
None listed